NURO
vs
S&P 500
NURO
S&P 500
Over the past 12 months, NURO has underperformed S&P 500, delivering a return of +5% compared to the S&P 500's +18% growth.
Stocks Performance
NURO vs S&P 500
Performance Gap
NURO vs S&P 500
Performance By Year
NURO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
NeuroMetrix Inc
Glance View
NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. The company is headquartered in Waltham, Massachusetts and currently employs 23 full-time employees. The company went IPO on 2004-07-22. The firm is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. The company has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.
